Sativex is the only regulatory-approved cannabinoid treatment
for patients with MS spasticity1,2

New
bottle and packaging
Image
box

GW Pharmaceuticals
developed and have always
manufactured Sativex.
Now we are increasing
engagement with patients and
healthcare professionals,
we have brought the
marketing and
commercialisation of
Sativex in-house, too

Listening to your feedback

 

We’ve added a blue marker to the nozzle so it’s easy for patients to direct the spray exactly where they want it.

 

Image
img

A fresh new look

 

We have updated the design of the packaging to reflect our new role in marketing Sativex.

 

Image
img

MS, multiple sclerosis.

References:
1. Sativex Summary of Product Characteristics.
2. NICE. NG144. November 2019.